Warning over Janssen's Nizoral tablets

30 July 2013

The US Food and Drug Administration is taking action over anti-fungal Nizoral (ketoconazole) oral tablets made by Janssen Pharmaceutical, a subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ), warning that it can cause severe liver injuries.

The FDA is also warning that it can cause adrenal gland problems and advising that it can lead to harmful drug interactions with other medications.

The Wall Street Journal reported that Johnson & Johnson said the manufacture of the tablets for the US market had been suspended before the FDA announcement. The European Medicines Agency’s Committee on Medicinal Products for Human Use (CHMP) this month recommended against continued sale of ketoconazole-containing products in Europe ( The Pharma Letter July 26), but that the company continues to sell the tablets in some other countries, according to the WSJ.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical